SCHEMBL2747950

SCHEMBL2747950

CC1(C)CCC(C)(C)c2cc(S(=O)(=O)Nc3ccsc3C(=O)O)ccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.56
CYP26A1 O43174 8/20 0.55
CYP26B1 Q9NR63 4/20 0.55
TSHR P16473 2/20 0.49
LMNA P02545 1/20 0.49
HPGD P15428 1/20 0.49
KDM4E B2RXH2 1/20 0.42
RARB P10826 4/20 0.40
RARG P13631 4/20 0.40
RXRA P19793 4/20 0.40
RXRB P28702 4/20 0.40
RXRG P48443 4/20 0.40
RARA P10276 3/20 0.40
MEN1 O00255 2/20 0.39
CYP3A4 P08684 2/20 0.39
KMT2A Q03164 2/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2748457 0.89 LMNA (0.65) ACLYCYP26A1CYP26B1TSHRLMNA
SCHEMBL2748520 0.77 ACLY (0.60) ACLYTSHRLMNAHPGDKDM4E
SCHEMBL2747681 0.77 ACLY (0.60) ACLYTSHRLMNAHPGDKDM4E
SCHEMBL7530793 0.76 LMNA (0.80) ACLYTSHRLMNAHPGDMEN1
SCHEMBL1200176 0.76 ACLY (0.64) ACLYTSHRLMNAHPGDKDM4E
SCHEMBL7531394 0.75 ACLY (0.67) ACLYTSHRLMNAHPGDKDM4E
SCHEMBL2747035 0.74 ACLY (0.62) ACLYTSHRLMNAHPGDMEN1
Hydrochloric Acid SCHEMBL7531671 0.74 ACLY (0.66) ACLYTSHRLMNAHPGDKDM4E
SCHEMBL532975 0.74 ACLY (0.69) ACLYTSHRLMNAHPGDKDM4E
SCHEMBL29541001 0.74 KEAP1 (0.54) CYP26A1CYP26B1LMNAHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178699-B2 Modulators of CCR9 receptor and methods of use thereof PFIZER INC. (US) 2012-05-15 US disclosed
US-8178699-B2 Modulators of CCR9 receptor and methods of use thereof PFIZER INC. (US) 2012-05-15 US disclosed
US-8178699-B2 Modulators of CCR9 receptor and methods of use thereof PFIZER INC. (US) 2012-05-15 US disclosed
EP-2220065-A2 MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2010-08-25 EP disclosed
US-20100029753-A1 MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. 2010-02-04 US disclosed
US-20100029753-A1 MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. 2010-02-04 US disclosed
US-20100029753-A1 MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. 2010-02-04 US disclosed
WO-2009017719-A2 MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2009-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029753-A1 MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF CCR9, CCR1, CCR4 ACLY 4546/4885CYP26A1 1603/4885CYP26B1 1402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.